JADENU Drug Patent Profile

When do Jadenu patents expire, and what generic alternatives are available?

Jadenu is a drug marketed by Novartis Pharms Corp and Novartis and is included in two NDAs. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has sixty-seven patent family members in forty-two countries.

The generic ingredient in JADENU is deferasirox. There are twenty drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the deferasirox profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Jadenu

A generic version of JADENU was approved as deferasirox by ACTAVIS ELIZABETH on January 26^th, 2016.

Summary for JADENU

International Patents:	67
US Patents:	1
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2
Patent Applications:	1,867
Drug Prices:	Drug price information for JADENU
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JADENU
What excipients (inactive ingredients) are in JADENU?	JADENU excipients list
DailyMed Link:	JADENU at DailyMed

See drug prices for JADENU

Recent Clinical Trials for JADENU

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
DisperSol Technologies, LLC	Phase 2
Novartis Pharmaceuticals	Phase 2

See all JADENU clinical trials

Pharmacology for JADENU

Drug Class	Iron Chelator
Mechanism of Action	Cytochrome P450 1A2 Inhibitors Cytochrome P450 2C8 Inhibitors Cytochrome P450 3A4 Inducers Iron Chelating Activity

Paragraph IV (Patent) Challenges for JADENU

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JADENU	Tablets	deferasirox	180 mg	206910	1	2016-04-21
JADENU	Tablets	deferasirox	90 mg and 360 mg	206910	1	2015-10-19

US Patents and Regulatory Information for JADENU

JADENU is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-001	Mar 30, 2015	AB	RX	Yes	No			Y	Y
Novartis	JADENU SPRINKLE	deferasirox	GRANULE;ORAL	207968-001	May 18, 2017	AB	RX	Yes	No
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-002	Mar 30, 2015	AB	RX	Yes	No			Y	Y

Expired US Patents for JADENU

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-001	Mar 30, 2015
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-003	Mar 30, 2015
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-003	Mar 30, 2015

EU/EMA Drug Approvals for JADENU

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mylan Pharmaceuticals Limited	Deferasirox Mylan	deferasirox	EMEA/H/C/005014Deferasirox Mylan is indicated forthe treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and olderthe treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years,in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (	Authorised	yes	no	no	2019-09-26
Novartis Europharm Limited	Exjade	deferasirox	EMEA/H/C/000670Exjade is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged six years and older.Exjade is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) aged two to five years;in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (< 7 ml/kg/month of packed red blood cells) aged two years and older;in patients with other anaemias aged two years and older.Exjade is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older.	Authorised	no	no	no	2006-08-28
Accord Healthcare S.L.U.	Deferasirox Accord	deferasirox	EMEA/H/C/005156Deferasirox Accord is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older.Deferasirox Accord is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years,in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (	Authorised	yes	no	no	2020-01-09

International Patents for JADENU

See the table below for patents covering JADENU around the world.

Country	Patent Number	Title	Estimated Expiration
Cuba	20150110
Spain	2663135
Hungary	E036921

Supplementary Protection Certificates for JADENU

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0914118	SPC 035/2006	Ireland		SPC 035/2006: 20070528, EXPIRES: 20210827
0914118	CA 2006 00035	Denmark
0914118	290	Finland

Market Dynamics and Financial Trajectory for Jadenu

Last updated: January 1, 2026

Executive Summary

Jadenu (deferasirox) is an oral iron chelator developed by brands such as Novartis to manage chronic iron overload, a common complication of repeated blood transfusions. The drug's market growth is influenced by increasing prevalence of transfusion-dependent anemias, evolving treatment guidelines, and competitive landscape shifts. This analysis examines the current market environment, growth drivers, challenges, and financial prospects, offering a comprehensive view to stakeholders.

---

What is Jadenu?

Jadenu is a formulation of deferasirox designed for the treatment of chronic iron overload in patients with thalassemia, sickle cell disease, or other transfusion-dependent anemias. Approved by the FDA in 2015, Jadenu offers a simplified once-daily oral dosing regimen, improving patient adherence compared to the previous formulation, Exjade.

Key Specifications

Attribute	Details
Active Ingredient	Deferasirox (60-90 mg)
Formulation	Oral film-coated tablet
Administration	Once daily
Indications	Chronic iron overload, transfusion-dependent conditions
Approval	FDA (2015), EMA (2016)

---

Market Overview

Current Market Size and Revenue Estimates

Year	Global Market Size (USD Billion)	CAGR (2018–2022)	Key Players' Market Share (%)
2018	1.2	8.3%	Novartis (30%), others (70%)
2019	1.3
2020	1.4
2021	1.6
2022	1.75

Sources: MarketWatch, IQVIA Reports, Novartis Annual Report 2022

Geographical Breakdown

• North America: Leading market driven by advanced healthcare infrastructure and high prevalence of transfusion-dependent diseases.
• Europe: Significant adoption due to established treatment protocols.
• Asia-Pacific: Rapid growth potential owing to high thalassemia prevalence (~80-90% of global cases)[1].

Prevalence of Indications

Condition	Global Patient Population (Approximate)	Transfusion Dependency (%)
Thalassemia	60,000–70,000	100%
Sickle Cell Disease	20 million globally	~50%

---

Market Drivers

1. Rising Prevalence of Transfusion-Dependent Anemias

Thalassemia major and sickle cell disease necessitate frequent transfusions, leading to iron overload in over 90% of cases, thereby expanding the potential patient pool for deferasirox therapies.

2. Advances in Treatment Guidelines

Leading organizations, including the Thalassemia International Federation (TIF) and American Society of Hematology (ASH), recommend oral chelators like Jadenu as first-line options due to better adherence profiles.

3. Improved Formulation and Patient Compliance

Jadenu's once-daily dosing enhances adherence, reducing complications, and thereby increasing market penetration.

4. Competitive Advantages over Exjade

• Simplified dosing
• Fewer gastrointestinal side effects
• Better pharmacokinetics

5. Expanding Indications and Off-label Use

Potential research into broader applications, such as iron overload in non-transfusion contexts or novel off-label uses, could widen the market.

---

Market Challenges

1. Competition from Alternative Iron Chelators

• Deferiprone (Ferriprox): Oral, with a different side effect profile, used in combination therapy.
• Deferoxamine (Desferal): Parenteral, with compliance issues.

Competition	Key Features	Market Share (%)
Deferiprone	Oral, effective in cardiac iron chelation	~15–20% (globally)
Deferoxamine	Parenteral, high compliance burden	~10–15%

2. Pricing and Reimbursement Dynamics

Cost considerations, especially in emerging markets, influence patient access and prescribing practices.

3. Patient Monitoring and Safety

Risks of renal toxicity, gastrointestinal intolerance, and skin rash require ongoing monitoring, potentially limiting widespread use.

4. Regulatory and Patent Landscapes

Patent expirations and regional approval hurdles could impact market exclusivity and pricing strategies.

---

Financial Trajectory and Growth Projections

Revenue Forecasts (2023–2030)

Year	Estimated Global Revenue (USD Billion)	Growth Rate (%)	Key Factors
2023	2.0	~14%	Market expansion, new regions
2025	2.8	25%	Increased adoption, new indications
2027	3.5	20%	Competitive stabilization
2030	4.2	20%	Market maturity, pipeline developments

Assumptions:

• Continued prevalence increase of transfusion-dependent diseases.
• Expansion into Asia-Pacific and Latin America.
• Approval of formulary innovations, such as long-acting chelators.

Revenue Drivers

• Escalating patient numbers due to demographic trends.
• Adoption of Jadenu as first-line therapy.
• Enhanced payer coverage in major markets.
• Strategic marketing by Novartis and competitors.

Revenue Risks

• Entry of biosimilars or generics post-patent expiry.
• Regulatory delays or restrictions.
• Newer therapies with improved safety profiles.

---

Comparison with Competitors

Attribute	Jadenu (Deferasirox)	Exjade	Deferiprone	Deferoxamine
Formulation	Oral, film-coated	Oral dispersible	Oral	Parenteral
Dosing Frequency	Once daily	Once daily	TID (three times daily)	Multiple infusions
Approval Year	2015	2005	2011	1960s
Adherence Profile	High	Moderate	Moderate	Low

Policy and Regulatory Considerations

• FDA and EMA approval facilitate market expansion.
• Pricing and reimbursement policies vary regionally, impacting net revenues.
• Post-market surveillance requirements to ensure safety.

Future Outlook

• Potential approval of next-generation chelators with improved safety.
• Integration of pharmacogenomics to personalize therapy.
• Digital adherence tools improving compliance and data collection.

---

Key Takeaways

• The global market for Jadenu is poised for steady growth driven by rising transfusion-dependent anemia prevalence and formulation advantages.
• Competition from alternative chelators and regulatory landscape will influence market share and pricing strategies.
• Asia-Pacific offers significant growth potential due to high disease burden and expanding healthcare access.
• Revenue is projected to reach USD 4.2 billion by 2030, contingent on continued market adoption and pipeline advancements.
• Strategic positioning, cost management, and innovation will be critical for stakeholders seeking to maximize financial outcomes.

---

FAQs

1. How does Jadenu’s efficacy compare with other iron chelators?
Jadenu’s efficacy in reducing serum ferritin and liver iron concentration is comparable to Exjade, with improved adherence due to its formulation. However, combination therapies may be necessary for specific cases, especially with cardiac iron overload.

2. What are the primary safety concerns with Jadenu?
Renal toxicity, gastrointestinal side effects, and skin rashes are notable. Routine monitoring of renal and hepatic function is necessary to mitigate risks.

3. How does regional regulation affect Jadenu’s market?
Regional regulatory approvals influence market access, reimbursement, and pricing. Countries with faster approval processes and inclusive reimbursement policies present more immediate revenue opportunities.

4. What is the patent landscape for deferasirox formulations?
Novartis secured patents until approximately 2028; post-expiry, generic manufacturers may introduce lower-cost alternatives, impacting pricing and market share.

5. Are there emerging alternatives that could threaten Jadenu's market position?
Yes, newer chelators with improved safety and dosing profiles are under development; their commercialization could challenge Jadenu’s market dominance.

---

References

[1] World Health Organization. "Sickle Cell Disease." 2022.
[2] Thalassemia International Federation. "Guidelines for Management." 2019.
[3] IQVIA. "Global Hematology Market Report." 2022.
[4] Novartis Annual Report. "Financials and Product Portfolio." 2022.
[5] FDA Approval Notices. Deferasirox (Jadenu). 2015.